Follicular Lymphoma Real-World Data
Follicular lymphoma accounts for about 20% of all non-Hodgkin lymphoma cases and represents roughly 3 to 5 new diagnoses per 100,000 people each year.
Qdata® can help lead to better treatments.
Qdata® Follicular Lymphoma is an exclusive dataset providing clear insight into treatment decisions, lines of therapy, and patient outcomes in real-world clinical practice.
Key Data Elements
Demographics
Molecular Markers
Histologic Grades
Performance Status
Anti-CD20 Therapy
Obinutuzumab
Lines of Therapy
Relapsed/Refractory
Newly Diagnosed
Survival & Outcomes
About Qdata® Follicular Lymphoma
Follicular lymphoma is a slow-growing (indolent) type of blood cancer called non-Hodgkin lymphoma. It originates in the lymphatic system when abnormal white blood cells (B-cells) gather in the lymph nodes, forming tumor clusters called follicles. While generally considered incurable, it is highly manageable and progresses slowly.
Follicular lymphoma medical research is aided by deeply abstracted, longitudinal follicular lymphoma patient records that reflect the clinical complexity of the disease and its relapsing course. The dataset includes histologic grade, transformation status, exposure to anti CD20 therapies such as obinutuzumab, and detailed multi line treatment sequencing. Each record is curated under oncology oversight and structured to support regulatory and development use.
The follicular lymphoma dataset maintains high completeness across the clinical variables that drive decision-making, including histologic grade, performance status, treatment intent, and documented outcomes.
Evidence in Action
Comprehensive Coverage Across the Full Follicular Lymphoma Continuum
With 83% of patients with outcome data, 80% of patients with performance status, and 7.3 years average length of follow-up, the dataset reflects the specialized care setting central to follicular lymphoma management.
Comprehensive Coverage of Follicular Lymphoma Treatment Modalities
The follicular lymphoma dataset reflects the full treatment landscape, from initial watchful waiting and frontline chemoimmunotherapy through targeted agents and relapsed/refractory regimens. Each line of therapy is documented in sequence, with detailed response and outcome capture across care settings.
Custom Data Curation
Need data tailored to your exact study design requirements?
Our purpose-built, fit-for-purpose datasets are designed to support rigorous research and confident decision-making. These datasets can be tailored
around custom inclusion and exclusion criteria, in addition to including all standard abstracted data elements.
Ready to Explore the Follicular Lymphoma Dataset?
Connect with our team to discuss your research objectives and receive a tailored data overview.